At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 200 enrolled
Drug / intervention
Vitamin E +1 moredrug
Likely dose
Vitamin E 200 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Vitamin E Dosing Study (VEDS): A Dose Finding Study of Vitamin E for the Treatment of Adult NAFLD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·interventional·Posted Mar 17, 2021·Updated May 14, 2026
In Brief
A Phase 2 clinical trial evaluating Vitamin E and Placebo for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Completed, enrolled 200 participants across 9 sites.
Detailed Summary
This is a multicenter, randomized, double masked, placebo-controlled, parallel treatment groups dosing trial of Vitamin E in adult nonalcoholic fatty liver disease (NAFLD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsDuke University, Liver Institute Northwest, Indiana University, St. Louis University, University of California, San Diego, University of Southern California, University of California, San Francisco, Virginia Commonwealth University, The Cleveland Clinic, Johns Hopkins Bloomberg School of Public Health
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedMar 2021
Enrollment StartAug 2022
Primary CompletionMar 2025
Study CompletionJun 2025
TodayJul 2026
First PostedMar 17, 2021
Enrollment StartAug 5, 2022
Primary CompletionMar 4, 2025
Study CompletionJun 30, 2025
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 5.3 years ago
Interventions
Vitamin Edrug
Participants will be assigned to take 200 IU, 400 IU, or 800 IU of vitamin E in matching capsules daily for 24 weeks
Placebodrug
Participants will take a placebo vitamin E capsule daily for 24 weeks